Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115689 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Laura L Michel und 33 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celgene Corporation, Eisai Inc, Hexal AG.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Whereas CDK4/6 inhibitors (CDK4/6i) are the standard first-line therapy for patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) metastatic breast cancer, guidelines on treatment options after progression on CDK4/6i are more diverse. Chemotherapy is recommended if a patient develops endocrine resistance or experiences a visceral crisis. However, the impact of the choice of chemotherapy remains unknown. METHODS: HRpos/HER2neg patients who received first-line CDK4/6i, followed by second-line chemotherapy (N = 215) were selected from the prospective PRAEGNANT registry (NCT02338167). Cox regression analyses were used to evaluate the correlation between the choice of chemotherapy (capecitabine monotherapy, capecitabine + bevacizumab, taxane monotherapy, taxane + bevacizumab, anthracycline, other chemotherapeutics) and progression-free survival (PFS) and overall survival (OS). RESULTS: Patients who received second-line chemotherapy mostly had high-grade tumors (G2: 62.3 %, G3: 33.3 %), visceral metastases (62.3 %) and developed metastatic disease following a primary breast cancer diagnosis (73.8 %). Capecitabine was the most common regimen (25.1 %), followed by taxane + bevacizumab (17.2 %). When adjusting for other prognostic factors (age, BMI, grading, ECOG, metastasis group and time to metastases), the choice of chemotherapy did not influence PFS (p = 0.16) nor OS (p = 0.47). Adjusted hazard ratios for PFS were lowest in regimens with bevacizumab (capecitabine as reference; capecitabine + bevacizumab: 0.53 (95 %CI: 0.29, 0.97); taxane + bevacizumab: 0.64 (95 %CI 0.35, 1.15)). CONCLUSION: Although the choice of chemotherapy post-CDK4/6i did not significantly affect PFS or OS, combinations with bevacizumab may have some benefit. Nevertheless, considering side effects may be most important when choosing the type of second-line chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC-EMN), Erlangen, Germany.
- Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
- Department of Gynecology, Halle University Hospital, Halle, Germany.
- Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC-EMN), Erlangen, Germany;…
- Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
Förderung
- Celgene Corporation
- Eisai Inc
- Hexal AG
- Pfizer
- Roche Germany Holding GmbH
- Daiichi Sankyo Europe GmbH
- AstraZeneca PLC
- Novartis Pharma GmbH
Zitieren
APA
Michel, L. L., Ziegler, P., Kreis, P., Hartkopf, A. D., Wallwiener, M., Häberle, L., John, N., Kolberg, H. C., Hadji, P., Tesch, H., Ettl, J., Lüftner, D., Müller, V., Belleville, E., Wimberger, P., Enzinger, H. M., Huebner, H., Uhrig, S., Hack, C. C., …, & Engler, T. (2025). Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115689
Vancouver
Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, et al. Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115689
BibTeX
@article{Michel2025,
author = {Michel, Laura L and Ziegler, Philipp and Kreis, Philipp and Hartkopf, Andreas D and Wallwiener, Markus and Häberle, Lothar and John, Nelson and Kolberg, Hans-Christian and Hadji, Peyman and Tesch, Hans and Ettl, Johannes and Lüftner, Diana and Müller, Volkmar and Belleville, Erik and Wimberger, Pauline and Enzinger, Hans-Martin and Huebner, Hanna and Uhrig, Sabrina and Hack, Carolin C and Krabisch, Petra and Fasching, Peter A and Wuerstlein, Rachel and Untch, Michael and Ditsch, Nina and Hein, Alexander and Janni, Wolfgang and Taran, Florin-Andrei and Lux, Michael P and Wallwiener, Diethelm and Brucker, Sara Y and Fehm, Tanja N and Schneeweiss, Andreas and Goossens, Chloë and Engler, Tobias},
title = {Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115689}
}
EUVIMED